1 Reduction of Stent Thrombosis in Patients with Acute Coronary Syndrome Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51 JACC - Journal of the American College of Cardiology, April 26, 2013
2 Anger and the Heart: Perspectives on Cardiac Risk, Mechanisms and Interventions Progress in Cardiovascular Diseases , May 1, 2013
3 Long-term clinical follow-up of the multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES) European Heart Journal, April 22, 2013
4 The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome Cardiology, May 9, 2013
5 Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis Annals of Rheumatic Diseases, May 7, 2013
6 Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial The Lancet Oncology, May 3, 2013
7 Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study Investigational New Drugs, April 30, 2013
8 Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature Lupus, April 25, 2013
9 Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II European Heart Journal, April 30, 2013 Review Article
10 Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma Clinical Cancer Research, May 14, 2013
Sponsor
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor